Evonik invests US$100 million to upgrade Indiana drug substance CDMO site

  • Evonik Venture Capital GmbH will invest USD 100 million over five years to upgrade its Tippecanoe, Indiana drug-substance CDMO site.
  • Modernization targets key equipment including 100 m3 reactors, aiming to boost reliability, automation, and operating efficiency.
  • Plan positions the facility to capture rising demand for US-based API manufacturing as supply chains shift toward Western production.
  • Upgrade expands capability for more complex small-molecule APIs, including high-potency work, supporting Evonik’s push toward a more balanced global asset footprint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Venture Capital GmbH published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.